In the following, experimental proof-of-concept studies revealed that inhibition of TRPV4 was capable of preventing and resolving pulmonary edema caused by heart failure [11], while the TRPV4-activator, GSK1016790A, produces endothelial/epithelial barrier disruption, lung edema, and circulatory collapse in rodents [12,14]. This evidence concerns the gene TRPV4 and pulmonary edema.